Skip to main content
. 2018 Nov 29;27(3):320–325. doi: 10.1016/j.jsps.2018.11.014

Table 2.

Students awareness of the therapeutic and side effects of cannabis and their attitudes toward cannabis abuse and legalisation

Questions and statements Recreational marijuana use
Year of the study
yes
N (%)
no
N (%)
p third
N (%)
fifth
N (%)
sixth
N (%)
p
Knowledge I am familiar with the possible therapeutic effect of cannabis yes 99 (94.3) 159 (75.4) <0.001 99 (76.2) 81 (89.0) 78 (82.1) 0.052
no 6 (5.7) 52 (24.6) 31 (23.8) 10 (11.0) 17 (17.9)
I am familiar with the side effects of cannabis yes 87 (82.9) 118 (55.9) <0.001 83 (63.8) 67 (73.6) 55 (57.9) 0.079
no 18 (17.1) 93 (44.1) 47 (36.2) 24 (26.4) 40 (42.1)



Abuse The use of cannabis for therapeutic purposes can cause addiction yes 48 (45.7) 148 (70.1) <0.001 83 (63.8) 56 (61.5) 57 (60.0) 0.836
no 57 (54.3) 63 (29.9) 47 (36.2) 35 (39.5) 38 (40.0)
The use of cannabis for therapeutic purposes would cause drug abuse yes 88 (83.8) 195 (92.4) 0.031 117 (90.0) 83 (91.2) 83 (87.4) 0.677
no 17 (16.2) 16 (7.6) 13 (10.0) 8 (8.8) 12 (12.6)
The use of cannabis for therapeutic purposes may be the gateway to hard drugs use yes 45 (42.9) 134 (63.5) 0.001 76 (58.5) 58 (63.7) 45 (47.4) 0.068
no 60 (57.1) 77 (36.5) 54 (41.5) 33 (26.3) 50 (52.6)



Legislation The use of cannabis requires the development of clear guidelines yes 98 (93.3) 202 (95.7) 0.519 121 (93.1) 89 (97.8) 90 (28.5) 0.287
no 7 (6.7) 9 (4.3) 9 (7.9) 2 (2.2) 5 (1.6)
I am aware that in some countries therapeutic use of cannabis has been approved yes 103 (98.1) 195 (92.4) 0.073 122 (93.8) 87 (95.6) 89 (93.7) 0.817
no 2 (1.9) 16 (7.6) 8 (6.2) 4 (4.4) 6 (6.3)
I am familiar with the current legalization process of cannabis in Serbia yes 57 (54.3) 79 (37.4) 0.006 52 (40.0) 46 (50.5) 38 (40.0) 0.230
no 48 (45.7) 132 (62.6) 78 (60.0) 45 (49.5) 57 (60.0)
The use of cannabis for therapeutic purposes should be legalized in Serbia yes 90 (85.7) 150 (71.1) 0.006 94 (72.3) 67 (73.6) 79 (83.2) 0.14
no 15 (14.3) 61 (28.9) 36 (27.7) 24 (26.4) 16 (16.8)